Kestra Medical Technologies (NASDAQ:KMTS) Raised to Hold at Wall Street Zen

Kestra Medical Technologies (NASDAQ:KMTS) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

Separately, Wells Fargo & Company dropped their price target on Kestra Medical Technologies from $28.00 to $27.00 and set an “overweight” rating on the stock in a research note on Thursday, July 17th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $27.33.

Kestra Medical Technologies Price Performance

Shares of KMTS stock opened at $24.94 on Friday. Kestra Medical Technologies has a 12 month low of $13.25 and a 12 month high of $27.71. The company has a debt-to-equity ratio of 0.23, a current ratio of 6.84 and a quick ratio of 6.72. The business’s 50-day moving average price is $17.33 and its 200-day moving average price is $19.99.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Jennison Associates LLC purchased a new position in shares of Kestra Medical Technologies in the 1st quarter valued at approximately $1,869,000. Eventide Asset Management LLC bought a new position in Kestra Medical Technologies during the 1st quarter valued at approximately $6,853,000. Omega Fund Management LLC bought a new position in Kestra Medical Technologies during the 1st quarter valued at approximately $44,754,000. Alyeska Investment Group L.P. bought a new position in Kestra Medical Technologies during the 1st quarter valued at approximately $2,492,000. Finally, Caas Capital Management LP bought a new position in Kestra Medical Technologies during the 1st quarter valued at approximately $1,470,000.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.